James M. Mock - 10 Sep 2026 Form 4 Insider Report for Moderna, Inc. (MRNA)

Reporting relationship: Chief Financial Officer
Issuer ticker: MRNA
Reported as of: 10 Sep 2026
Net transaction value: -$4,685,094
SEC form: 4
Accepted by SEC: 14 Sep 2026, 16:25:21 UTC
Prior SEC filing: 08 Sep 2026
Source filing: View source filing
Reporting owner signature: /s/ James Dillon, As Attorney-in-Fact

Key filing fact

James M. Mock filed Form 4 for Moderna, Inc. (MRNA) on 14 Sep 2026.

Key facts

This page summarizes James M. Mock's Form 4 filing for Moderna, Inc. (MRNA).
4 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 14 Sep 2026, 16:25.

Change

Previous filing in this sequence was filed on 08 Sep 2026.
Current net transaction value: -$4,685,094.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001736359 Primary reporting owner

Mock James M

Relationship: Chief Financial Officer
Address: C/O MODERNA, INC., 325 BINNEY STREET, CAMBRIDGE
Signature: /s/ James Dillon, As Attorney-in-Fact
Signature date: 14 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MRNA transaction

Common Stock

Options Exercise

Transaction value
Shares: +19,836
Change %: +27%
Price: $30.96^*
Shares after: 94,211
Date: 10 Sep 2026
Ownership: Direct
Footnotes: F1

MRNA transaction

Common Stock

Sale

Transaction value: $2,667,744
Shares: -19,836
Change %: -21%
Price: $134.49
Shares after: 74,375
Date: 10 Sep 2026
Ownership: Direct
Footnotes: F1

MRNA transaction

Common Stock

Sale

Transaction value: $2,017,350
Shares: -15,000
Change %: -20%
Price: $134.49
Shares after: 59,375
Date: 10 Sep 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MRNA transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -19,836
Change %: -31%
Price: $0.000000^*
Shares after: 43,642
Date: 10 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 19,836
Exercise price: $30.96
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 9, 2026.

Footnote F2

25% of this option vested and become exercisable on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter.